54 related articles for article (PubMed ID: 7224448)
1. [Normalization of lipid levels in an 87-year-old woman with a type III dysbetalipoproteinemia by ethinyl estradiol (author's transl)].
De Gennes JL; Dairou F; Epelboin S; Tuffert J
Ann Med Interne (Paris); 1980; 131(7):410-5. PubMed ID: 7224448
[TBL] [Abstract][Full Text] [Related]
2. A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia.
Stuyt PM; Demacker PN; van't Laar A
Horm Metab Res; 1986 Sep; 18(9):607-10. PubMed ID: 3465673
[TBL] [Abstract][Full Text] [Related]
3. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
Canzler H; Bojanovski D
Artery; 1980; 8(2):171-8. PubMed ID: 7458684
[TBL] [Abstract][Full Text] [Related]
4. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.
de Knijff P; van den Maagdenberg AM; Frants RR; Havekes LM
Hum Mutat; 1994; 4(3):178-94. PubMed ID: 7833947
[TBL] [Abstract][Full Text] [Related]
5. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
6. [Serum lipids and lipoproteins during therapy in a patient with familial type III hyperlipoproteinemia].
Tozuka M; Hidaka H; Kanai M; Horigome R; Takase Y
Rinsho Byori; 1983 Dec; 31(12):1317-24. PubMed ID: 6676485
[No Abstract] [Full Text] [Related]
7. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
Batukan C; Muderris II
Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
[TBL] [Abstract][Full Text] [Related]
9. Clomiphene-associated combined hyperlipidemia: a case report.
Gillett MJ; Burnett JR; Yeap D
J Reprod Med; 2006 Jul; 51(7):587-90. PubMed ID: 16913553
[TBL] [Abstract][Full Text] [Related]
10. Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
Burnside NJ; Alberta L; Robinson-Bostom L; Bostom A
J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S281-4. PubMed ID: 16227109
[TBL] [Abstract][Full Text] [Related]
11. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
12. Oxandrolone and plasma triglyceride reduction: effect on triglyceride-rich and high density lipoproteins.
Hara T; Miller JP; Gotto AM; Patsch JR
Artery; 1981; 9(5):328-41. PubMed ID: 7316782
[TBL] [Abstract][Full Text] [Related]
13. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome.
Gul OB; Somunkiran A; Yucel O; Demirci F; Ozdemir I
Arch Gynecol Obstet; 2008 Jan; 277(1):25-30. PubMed ID: 17618446
[TBL] [Abstract][Full Text] [Related]
14. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
Winkler UH; Sudik R
Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
[TBL] [Abstract][Full Text] [Related]
15. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
Brynhildsen J; Hammar M
Maturitas; 2005 Apr; 50(4):344-52. PubMed ID: 15780536
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
Feussner G; Kurth B; Lohrmann J
Eur J Med Res; 1997 Apr; 2(4):165-8. PubMed ID: 9110923
[TBL] [Abstract][Full Text] [Related]
17. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
18. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
Olson WH; Lippman JS; Robisch DM
Int J Fertil Womens Med; 1998; 43(6):286-90. PubMed ID: 9920537
[TBL] [Abstract][Full Text] [Related]
19. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
Wechsler JG; Hutt V; Klör HU; Ditschuneit H
Artery; 1980; 8(6):519-29. PubMed ID: 7259531
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of lipoprotein metabolic disorders during treatment with oral contraceptives].
Titov VN; Sanfirova VM; Khodakova TD
Farmakol Toksikol; 1980; 43(3):345-8. PubMed ID: 7449976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
